{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:46:48Z","timestamp":1792457208447,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["5x1000"],"award-info":[{"award-number":["5x1000"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lungcan.2026.109533","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:54:48Z","timestamp":1783781688000},"page":"109533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT"],"prefix":"10.1016","volume":"219","author":[{"given":"Filippo","family":"de Marinis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-5407","authenticated-orcid":false,"given":"Tina","family":"Cascone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-980X","authenticated-orcid":false,"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1333-6622","authenticated-orcid":false,"given":"Ilaria","family":"Attili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8748-7015","authenticated-orcid":false,"given":"Cesare","family":"Gridelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109533_b0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"35\u201342","key":"10.1016\/j.lungcan.2026.109533_b0010","article-title":"Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer","volume":"28","author":"Arriagada","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3552\u20133559","key":"10.1016\/j.lungcan.2026.109533_b0015","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/CCO.0b013e328011bed9","article-title":"Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer","volume":"19","author":"De Pauw","year":"2007","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0025","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109533_b0030","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432500","article-title":"Moving immunotherapy into the treatment of resectable non\u2013small cell lung cancer","volume":"44","author":"Chaft","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.lungcan.2026.109533_b0035","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109533_b0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109533_b0045","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109533_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","author":"Spicer","year":"2024","journal-title":"J. Thor. Oncol."},{"issue":"179\u2013190","key":"10.1016\/j.lungcan.2026.109533_b0055","article-title":"Immunotherapy for early-stage non-small cell lung cancer: a practical guide of current controversies","volume":"26","author":"Phillips","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109533_b0060","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109533_b0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8501","article-title":"Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study","volume":"41","author":"Lu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2026.109533_b0075","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jtho.2025.09.128","article-title":"MA04.08 perioperative tislelizumab for resectable non-small cell lung cancer: final analysis of RATIONALE-315","volume":"20","author":"Yue","year":"2025","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0080","article-title":"295P Neoadjuvant chemoimmunotherapy with sequential extended toripalimab in resectable stage II-IIIB NSCLC (NEXTORCH): First-stage data of the Simon's two-stage design","volume":"11","author":"Zhang","year":"2026","journal-title":"ESMO Open"},{"issue":"1240\u20131252","key":"10.1016\/j.lungcan.2026.109533_b0085","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109533_b0090","doi-asserted-by":"crossref","first-page":"S1607","DOI":"10.1016\/j.annonc.2025.09.079","article-title":"LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671","volume":"36","author":"Wakelee","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106531","article-title":"223MO Five-year outcomes of participants with pathological complete response (pCR) enrolled in the KEYNOTE-671 trial of perioperative pembrolizumab (pembro) in early-stage NSCLC","volume":"11","author":"Majem","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109533_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106530","article-title":"222MO Exploratory analysis of participants without pathological complete response (pCR) in the KEYNOTE-671 study of perioperative pembrolizumab (pembro) in early-stage NSCLC after 5\u00a0years of follow-up","volume":"11","author":"Reck","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109533_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8010","article-title":"Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: updated survival and biomarker analyses from CheckMate 77T","volume":"43","author":"Cascone","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0110","unstructured":"Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer, https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/imfinzi-approved-in-eu-for-aegean.html (2025, accessed January 2026 2026)."},{"key":"10.1016\/j.lungcan.2026.109533_b0115","unstructured":"Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence, https:\/\/www.onclive.com\/view\/perioperative-pembrolizumab-wins-approval-in-europe-for-resectable-nsclc-at-high-risk-of-recurrence (2024, accessed January 2026 2026)."},{"key":"10.1016\/j.lungcan.2026.109533_b0120","unstructured":"Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo\u00ae (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression \u22651%, https:\/\/news.bms.com\/news\/details\/2025\/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Perioperative-Regimen-of-Neoadjuvant-Opdivo-nivolumab-and-Chemotherapy-Followed-by-Adjuvant-Opdivo-for-Resectable-High-Risk-Non-Small-Cell-Lung-Cancer-with-PD-L1-Expression-1\/default.aspx (2025, accessed January 2026 2026)."},{"key":"10.1016\/j.lungcan.2026.109533_b0125","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jtho.2024.09.069","article-title":"OA13.03 perioperative durvalumab for resectable NSCLC (R-NSCLC): updated outcomes from the phase 3 AEGEAN trial","volume":"19","author":"Heymach","year":"2024","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0130","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0191-2023","article-title":"Mediastinal staging of nonsmall cell lung cancer: what's new?","volume":"21","author":"Bradley","year":"2025","journal-title":"Breathe"},{"key":"10.1016\/j.lungcan.2026.109533_b0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(26)00051-2","article-title":"Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration","volume":"14","author":"Dingemans","year":"2026","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2026.109533_b0140","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2025.1115","article-title":"Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III Non\u2013small cell lung cancer","volume":"11","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0145","doi-asserted-by":"crossref","first-page":"S1606","DOI":"10.1016\/j.annonc.2025.09.077","volume":"36","author":"Reck","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0150","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2025.3494","article-title":"Neoadjuvant chemoimmunotherapy in stage III non\u2013small cell lung cancer","volume":"11","author":"Bertolaccini","year":"2025","journal-title":"JAMA Oncology"},{"issue":"1301\u20131311","key":"10.1016\/j.lungcan.2026.109533_b0155","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0160","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109533_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108367","article-title":"258 HORIZON-01: a phase I\u2013III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)","volume":"200","author":"Popat","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109533_b0175","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/curroncol32020110","article-title":"Perioperative chemo-immunotherapy in non-oncogene-addicted resectable non-small cell lung cancer (NSCLC): Italian expert panel meeting","volume":"32","author":"de Marinis","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0180","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","article-title":"Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1569864","key":"10.1016\/j.lungcan.2026.109533_b0185","article-title":"Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2026.109533_b0190","unstructured":"EMA Recommends Approval of Neoadjuvant Nivolumab\/Chemotherapy in Resectable NSCLC, https:\/\/www.onclive.com\/view\/ema-recommends-approval-of-neoadjuvant-nivolumab-chemotherapy-in-resectable-nsclc (2023, accessed January 2026 2026)."},{"key":"10.1016\/j.lungcan.2026.109533_b0195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s43018-025-01104-z","article-title":"Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis","volume":"7","author":"Provencio","year":"2026","journal-title":"Nat. Cancer"},{"issue":"281\u2013289","key":"10.1016\/j.lungcan.2026.109533_b0200","article-title":"Clinical characteristics and surgical outcomes of patients receiving perioperative pembrolizumab in KEYNOTE-671","volume":"121","author":"Liberman","year":"2026","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109533_b0205","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jtho.2025.06.015","article-title":"Surgical outcomes with neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in resectable NSCLC","volume":"20","author":"Mitsudomi","year":"2025","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0210","doi-asserted-by":"crossref","first-page":"e2517953","DOI":"10.1001\/jamanetworkopen.2025.17953","article-title":"Clinical outcomes of perioperative immunotherapy in resectable non\u2013small cell lung cancer","volume":"8","author":"Desai","year":"2025","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.lungcan.2026.109533_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108482","article-title":"Immunotherapy in advanced non-small cell lung cancer: what to do for the \u2018Invisible\u2019 patients after IPSOS trial results?","volume":"202","author":"Gridelli","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109533_b0220","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jtho.2025.07.115","article-title":"Brief report: post hoc validation of platinum ineligibility in NSCLC from the phase III IPSOS study","volume":"20","author":"Peters","year":"2025","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108635","article-title":"ETOP 25-23 ADOPT-lung: an international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC","volume":"206","author":"Schmid","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109533_b0230","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0235","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2025.43.16_suppl.8009","article-title":"Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial","volume":"43","author":"Reck","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0240","article-title":"Clinical significance of perioperative minimal residual disease detected by circulating tumor DNA in patients with lung cancer with a long follow-up data: an exploratory study","volume":"6","author":"Ohara","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109533_b0245","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.014","article-title":"PL02.08 perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816","volume":"19","author":"Forde","year":"2024","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2026.109533_b0250","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jtho.2024.11.004","article-title":"Adjuvant immunotherapy should be used in patients with non-small cell carcinoma with a pathologic complete response to neoadjuvant immunotherapy","volume":"20","author":"Uprety","year":"2025","journal-title":"J. Thor. Oncol."},{"issue":"100384","key":"10.1016\/j.lungcan.2026.109533_b0255","article-title":"Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC: a meta-analysis","volume":"3","author":"Rosner","year":"2022","journal-title":"JTO Clin. Res. Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:24:55Z","timestamp":1791271495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"alternative-id":["S0169500226005945"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109533","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109533"}}